Drug candidates that are related to a common metabolite called adenosine inhibit inflammation and reduce bone destruction in artificial joints. The finding suggests a potential approach to increasing the durability of prosthetic implants.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Teeny, S. M., York, S. C., Mesko, J. W. & Rea, R. E. J. Arthroplasty 18, 954–962 (2003).
Purdue, P. E., Koulouvaris, P., Nestor, B. J. & Sculco, T. P. HSS J. 2, 102–113 (2006).
Mediero, A. et al. Sci. Transl. Med. 4, 135ra65 (2012).
Holt, G., Murnaghan, C., Reilly, J. & Meek, R. M. Clin. Orthop. Related Res. 460, 240–252 (2007).
Linden, J. Adv. Pharmacol. 61, 95–114 (2011).
Murphree, L. J., Sullivan, G. W., Marshall, M. A. & Linden, J. Biochem. J. 391, 575–580 (2005).
Ren, K. et al. Mol. Pharmaceut. 8, 1043–1051 (2011).
Henson, P. M. Nature Immunol. 6, 1179–1181 (2005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author holds shares in Lewis and Clark Pharmaceuticals, LLC, a company that produces drugs targeting adenosine receptors.
Rights and permissions
About this article
Cite this article
Linden, J. Longer life for artificial joints. Nature 487, 179–180 (2012). https://doi.org/10.1038/487179a
Published:
Issue Date:
DOI: https://doi.org/10.1038/487179a
